Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Cardiotoxicity 6Lymphoma, Non-Hodgkin 4Lymphoma 3Breast Neoplasms 3Prostatic Neoplasms 2Multiple Myeloma 2Leukemia 2Cardiovascular Diseases 2Small Cell Lung Carcinoma 1Obesity 1Neoplasms 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Metastatic Solid Tumors 1Metabolic Syndrome 1Melanoma 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Primary Effusion 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1Lung Neoplasms 1Leukemia, Hairy Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Heart Failure 1Epstein-Barr Virus Infections 1

Interventions

Cyclophosphamide 12fludarabine phosphate 7fludarabine 7venetoclax 6blinatumomab 6Cytarabine 5Lenalidomide 4Dexamethasone 4Blood Specimen Collection 4Azacitidine 4obinutuzumab 3Rituximab 3Radiotherapy 3Melphalan 3Immunotherapy, Adoptive 3pembrolizumab 2daratumumab 2Neoadjuvant Therapy 2Idarubicin 2Chemotherapy, Adjuvant 2Capecitabine 2trastuzumab deruxtecan 1tislelizumab 1tisagenlecleucel 1thymoglobulin 1tetrathiomolybdate 1talquetamab 1tagraxofusp 1sacituzumab govitecan 1sabatolimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × Echocardiography × 1 year × Clear all
NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
175 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡